Xichun Hu
- Oncology top 5%
- Pulmonary and Respiratory Medicine top 5%
- Radiology, Nuclear Medicine and Imaging top 5%
- Cancer Research top 10%
- Molecular Biology
- Topics
- HER2/EGFR in Cancer Research (40 papers)Advanced Breast Cancer Therapies (35 papers)Cancer Treatment and Pharmacology (28 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Xichun Hu
80 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 80
- Oncology 891
- Pulmonary and Respiratory Medicine 518
- Radiology, Nuclear Medicine and Imaging 260
- Cancer Research 189
- Molecular Biology 161
Countries citing papers authored by Xichun Hu
This map shows the geographic impact of Xichun Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xichun Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xichun Hu more than expected).
Fields of papers citing papers by Xichun Hu
This network shows the impact of papers produced by Xichun Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xichun Hu. The network helps show where Xichun Hu may publish in the future.
Co-authorship network of co-authors of Xichun Hu
This figure shows the co-authorship network connecting the top 25 collaborators of Xichun Hu. A scholar is included among the top collaborators of Xichun Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xichun Hu. Xichun Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).breakdown → | 52 |
| 4 | 2 | |
| 5 | 1 | |
| 6 | 1 | |
| 7 | 36 | |
| 8 | 26 | |
| 9 | 0 | |
| 10 | 8 | |
| 11 | 11 | |
| 12 | 28 | |
| 13 | 3 | |
| 14 | 34 | |
| 15 | 247 | |
| 16 | 10 | |
| 17 | 6 | |
| 18 | 49 | |
| 19 | 26 | |
| 20 | 29 |
About Xichun Hu
Xichun Hu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 86 papers that have together received 1.1k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (40 papers), Advanced Breast Cancer Therapies (35 papers) and Cancer Treatment and Pharmacology (28 papers). The work is most often cited by research in Oncology (891 citations), Pulmonary and Respiratory Medicine (518 citations) and Genetics (142 citations). Xichun Hu has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Zhongsheng Tong, Biyun Wang, Xiaoyu Zhu, Jianjun Zou, Zefei Jiang, Shusen Wang, Wěi Li, Fei Ma, Huiping Li and Binghe Xu. Their work appears in journals such as Journal of Clinical Oncology, Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.